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SCIENTIFIC OPINION 
Guidance on the scientific requirements for health claims related to 
physical performance
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
The Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked by the European Food 
Safety Authority (EFSA) to draft guidance on scientific requirements for health claims related to 
physical performance. This guidance has been drawn from scientific opinions of the NDA Panel on 
such health claims. Thus, this guidance document represents the views of the NDA Panel based on the 
experience gained to date with the evaluation of health claims in this area. It is not intended that the 
document should include an exhaustive list of beneficial effects and studies/outcome measures which 
are acceptable. Rather, it presents examples drawn from evaluations already carried out in order to 
illustrate the approach of the Panel, as well as some examples which are currently under consideration 
within ongoing evaluations. A draft of this guidance document, endorsed by the NDA Panel on 
24 November 2011, was released for public consultation from 19 December 2011 to 09 March 2012. 
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BACKGROUND AS PROVIDED BY EFSA 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims 
and establishes rules governing the Community authorisation of health claims made on foods. 
According to the Regulation, health claims should only be authorised for use in the Community after a 
scientific assessment of the highest possible standard has been carried out by EFSA. 
EFSA and its NDA Panel have been engaging in consultation with stakeholders and have published 
guidance on scientific substantiation of health claims since 2007
5
. Most recently, a briefing document 
on scientific evaluation of health claims was published for consultation in April 2010, followed by a 
technical meeting with experts from the food industry, Member States and the European Commission 
in Parma, in June 2010
6
.  
Based on experiences gained with the evaluation of health claims, and to further assist applicants in 
preparing and submitting their applications for the authorisation of health claims, the NDA Panel is 
asked to develop guidance documents on the scientific requirements for the substantiation of health 
claims in selected areas, in addition to the guidance for the scientific substantiation of health claims 
related to gut and immune function (EFSA-Q-2010-01139).  
TERMS OF REFERENCE AS PROVIDED BY EFSA 
The NDA Panel is requested by EFSA to develop guidance documents on the scientific requirements 
for health claims in the following areas:  
 Post-prandial blood glucose responses/blood glucose control 
 Weight management, energy intake and satiety 
 Protection against oxidative damage 
 Cardiovascular health 
 Bone, joints, and oral health 
 Neurological and psychological functions 
 Physical performance 
Specific issues to be addressed in these guidance documents include: 
 which claimed effects are considered to be beneficial physiological effects? 
 which studies/outcome measures are appropriate for the substantiation of function claims and 
disease risk reduction claims? 
Each guidance document should be subject to public consultation, and may be followed up as 
appropriate by scientific meetings with experts in the field. 
Before the adoption of each guidance document by the NDA Panel the draft guidance shall be revised, 
taking into account the comments received during the public consultation. A report on the outcome of 
the public consultation shall be published for each guidance document. All guidance documents 
should be finalised by July 2012. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
5  http://www.efsa.europa.eu/en/nda/ndaclaims.htm 
6  http://www.efsa.europa.eu/en/ndameetings/docs/nda100601-ax01.pdf 
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ASSESSMENT 
1. Introduction 
To assist applicants in preparing and submitting their applications for the authorisation of health 
claims, EFSA and in particular its Scientific Panel on Dietetic Products, Nutrition and Allergies 
(NDA) has ongoing consultations with stakeholders, and has published guidance on the scientific 
substantiation of health claims since 2007
7
. In April 2010, a draft briefing document on the scientific 
evaluation of health claims was published for consultation, and was followed by a technical meeting 
with experts from the food industry, Member States and the European Commission in Parma, in 
June 2010. The draft briefing document has been transformed into a Panel output, taking into account 
the questions/comments received. This document constitutes the general guidance for stakeholders on 
the evaluation of Article 13.1, 13.5 and 14 health claims, and outlines the approach of the NDA Panel 
to the evaluation of health claims in general. In response to requests from industry, EFSA is engaged 
in further consultation with stakeholders, and is developing additional guidance on specific types of 
claims. 
The present guidance, prepared by the NDA Panel, on the scientific requirements for the 
substantiation of health claims on physical performance was, prior to its finalisation, endorsed by the 
NDA Panel on 24 November 2011 for public consultation, which was open from 19 December 2011 
to 09 March 2012. All the comments received that related to the remit of EFSA were assessed, and the 
guidance has been revised taking into consideration relevant comments. The comments received and a 
report on the outcome of the public consultation are published on the EFSA website. 
The guidance document focuses on two key issues regarding the substantiation of health claims 
related to physical performance: 
 claimed effects which are considered to be beneficial physiological effects. 
 studies/outcome measures which are considered to be appropriate for the substantiation of 
health claims. 
Issues which are related to substantiation and are common to health claims in general 
(e.g. characterisation of the food/constituent) are addressed in the general guidance for stakeholders 
on the evaluation of Article 13.1, 13.5 and 14 health claims
 8
. 
This document has been drawn from scientific opinions of the NDA Panel on health claims related to 
physical performance. Thus, it represents the views of the NDA Panel based on the experience gained 
to date with the evaluation of health claims in this area. The document should be read in conjunction 
with the general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health 
claims.  
It is not intended that the document should include an exhaustive list of beneficial effects and 
studies/outcome measures which are acceptable. Rather, it presents examples drawn from evaluations 
already carried out in order to illustrate the approach of the Panel, as well as some examples which 
are currently under consideration within ongoing evaluations. Given that health claims are often 
technically complex and unique, additional health relationships and outcome measures for claimed 
effects need to be considered in the context of a specific application. This guidance document may be 
updated in the future in light of additional experience gained with the evaluation of health claims. 
                                                     
7  http://www.efsa.europa.eu/en/ndaclaims/ndaguidelines.htm  
8  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2. General considerations 
2.1. Beneficial physiological effects 
According to Regulation (EC) No 1924/2006, the use of health claims shall only be permitted if the 
food/constituent for which the claim is made has been shown to have a beneficial physiological effect. 
In assessing each claim, the NDA Panel makes a scientific judgement on whether the claimed effect is 
considered to be a beneficial physiological effect in the context of the specific claim, as described in 
the information provided and taking into account the population group for whom the claim is 
intended. For function claims, a beneficial effect may relate to the maintenance or improvement of a 
function.  
The NDA Panel considers that the population group for which health claims are intended is the 
general (healthy) population or specific subgroups thereof, for example, elderly people, physically 
active subjects, or pregnant women. Applications for claims which specify target groups other than 
the general (healthy) population are the subject of ongoing discussions with the Commission and 
Member States with regard to their admissibility. 
The NDA Panel also considers whether the claimed effect is sufficiently defined to establish that the 
studies identified for substantiation of the claim were performed with (an) appropriate outcome 
measure(s) of that claimed effect. Reference to general, non-specific benefits of the nutrient or food 
for overall good health or health-related well-being may only be made if accompanied by a specific 
health claim. 
2.2. Studies/outcome measures appropriate for substantiation of claims 
As human studies are central for the substantiation of health claims, this document focuses in 
particular on such studies. In considering whether the studies provided are pertinent (i.e. studies from 
which conclusions can be drawn for the scientific substantiation of the claim), the NDA Panel 
addresses a number of questions, including: 
 Whether the studies have been carried out with the food/constituent for which the claim is 
made. This requirement means that there should be sufficient definition of the 
food/constituent for which the claim is made, and of the food/constituent which has been 
investigated in the studies which have been provided for substantiation of the claim. The 
evaluation also considers how the conditions under which the human studies were performed 
relate to the conditions of use (e.g. quantity and pattern of consumption of the 
food/constituent) proposed for the claim.  
 Whether the design and quality of the studies allow conclusions to be drawn for the scientific 
substantiation of the claim. The evaluation takes into account the hierarchy of evidence as 
described in the scientific and technical guidance of the EFSA NDA Panel
9
, for example, 
intervention studies generally provide stronger evidence than observational studies. 
Intervention studies should be appropriately conducted so as to minimise bias. In 
observational studies adequate control for factors other than the food/constituent known to 
have an impact on the claimed effect is important. Each health claim is assessed separately 
and there is no pre-established formula as to how many or what type of studies are needed to 
substantiate a claim. In this regard, the reproducibility of the effect of the food/constituent as 
indicated by consistency between studies is an important consideration.  
                                                     
9  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. Scientific and technical guidance for the 
preparation and presentation of an application for authorisation of a health claim (revision 1). EFSA Journal, 9(5):2170, 
36 pp. 
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 Whether the studies have been carried out in a study group representative of the population 
group for which the claim is intended. Can the results obtained in the studied population be 
extrapolated to the target population? For studies in groups (e.g. subjects with a disease) other 
than the target group for a claim (e.g. the general population), the NDA Panel considers on a 
case-by-case basis the extent to which it is established that extrapolation from the study group 
to the target group is biologically plausible.  
 Whether the studies used (an) appropriate outcome measure(s) of the claimed effect. For this, 
the NDA Panel considers what is generally accepted in the relevant research fields 
(e.g. guidelines published by scientific societies based on rigorous methodological 
approaches), and consults experts from various disciplines, as appropriate.  
3. Claims on physical performance  
Physical performance relates to the ability to complete certain physical tasks with higher intensity, 
faster, or with a higher power output. Improvement, maintenance or reduced loss of physical 
performance may be a beneficial physiological effect for individuals performing physical exercise for 
different reasons (e.g. athletes preparing for a competition or during a competition, and individuals 
engaged in physical work or recreational activities), but also for individuals performing common (non 
exercise-related) physical tasks. Information on the characteristics (e.g. type, duration and intensity) 
of the exercise or physical activity for which the claim is made may be important for the definition of 
the claimed effect (e.g. physical performance during short-term, high intensity exercise vs. longer-
term, endurance performance; single exercise bout vs. repeated bouts; weight bearing vs. non-weight 
bearing activities) and of the target population for the claim (e.g. athletes and elderly subjects). 
Outcome measures of physical performance which may be appropriate for the assessment of the 
claimed effect in humans in the context of a particular type of exercise or physical activity should be 
indicated (e.g. time spent to run a certain distance, distance cycled during a time-trial, throwing 
distance in javelin or shot put, jumping height, walking speed and number of chair-stands in a certain 
time).  
Some of the outcomes proposed (e.g. changes in maximum oxygen consumption (VO2max), muscle 
glycogen stores and substrate oxidation) are not direct measures of performance but could be used in 
support of a mechanism by which the food/constituent could exert the claimed effect on physical 
performance.   
The studies provided for the scientific substantiation of the claim should reflect the conditions of use 
for the claim. For example, when the food/constituent is consumed relative to the physical 
performance test (e.g. before or during exercise), or the duration of the intervention, may be of 
importance.  
4. Claims on endurance capacity  
Endurance capacity refers to the exercise time to fatigue when exercising at a constant workload or 
speed, generally at intensity <80 % VO2max. An increased endurance capacity may be a beneficial 
physiological effect for individuals performing physical exercise which is not limited by time 
(e.g. recreational running, walking, swimming, cycling and fitness training).   
The particular type of exercise (e.g. cycling, running and swimming) and the conditions (e.g. distance, 
power output and single bout vs. repeated bouts) in which endurance capacity is tested should be 
specified. The exercise time to fatigue under defined conditions can be assessed by using objective 
(e.g. cycling cadence, oxygen consumption and heart rate) or self-reported (e.g. with a validated 
questionnaire) measurements of physical fatigue.  
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Some of the outcomes proposed (e.g. changes in VO2max, muscle glycogen stores, and substrate 
oxidation) are not direct measures of endurance capacity but could be used in support of a mechanism 
by which the food/constituent could exert the claimed effect. 
5. Claims on muscle function 
The improvement, maintenance or reduced loss of muscle function (e.g. muscle strength) is 
considered a beneficial physiological effect. Outcome measures of muscle function which may be 
appropriate for the assessment of the claimed effect in humans in the context of a particular type of 
exercise or physical activity should be indicated (e.g. one repetition maximum weight lifting, 
isokinetic knee extension torque and isometric handgrip strength). Also changes in muscle structure 
(e.g. muscle mass, muscle shape, number and type of muscle fibres, muscle damage and muscle tissue 
repair) contributing to the improvement, maintenance or reduced loss of muscle function (e.g. muscle 
strength) can be considered beneficial physiological effects. Evidence on whether (and the extent to 
which) specific changes in muscle structure may lead to changes in muscle function should be 
provided, and will be considered on a case-by-case basis.   
Faster recovery from water loss, muscle fatigue, muscle soreness or muscle damage after exercise 
contributing to the restoration of muscle function (e.g. muscle strength), can be considered beneficial 
physiological effects. Subjective measures of muscle fatigue or muscle soreness may be used as 
supportive evidence in this context. 
6. Claims on physiological effects which may lead to an improvement in physical 
performance or endurance capacity 
Claims on specific physiological effects which may lead to an improvement in physical performance 
or endurance capacity have been proposed. These include, for example, reduction in perceived 
exertion/effort during exercise, or enhancement of water absorption during exercise. The context in 
which such changes may lead to changes in physical performance or endurance capacity 
(e.g. characteristics of the exercise or physical activity and the target population for which the claim is 
intended) should be provided, and will be considered on a case-by-case basis.  
Outcome measures which may be appropriate for the assessment of the claimed effects in humans 
should be indicated. For example, validated questionnaires could be used for the assessment of 
perceived exertion/effort during exercise. For self-reported outcome measures, adequate blinding of 
subjects and investigators to the intervention is particularly important.  
Claims related to changes in body composition have been addressed in the “Guidance on the scientific 
requirements for health claims related to appetite ratings, weight management, and blood glucose 
concentrations”10.  
                                                     
10  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2012. Guidance on the scientific requirements for health 
claims related to appetite ratings, weight management, and blood glucose concentrations. EFSA Journal, 10(3):2604, 
11 pp.  
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CONCLUSIONS 
The guidance document focuses on two key issues regarding the substantiation of health claims 
related to physical performance: 
 claimed effects which are considered to be beneficial physiological effects. 
 studies/outcome measures which are considered to be appropriate for the substantiation of 
health claims. 
The document has been drawn from scientific opinions of the NDA Panel on health claims related to 
physical performance. Thus, it represents the views of the NDA Panel based on the experience gained 
to date with the evaluation of health claims in this area. 
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GLOSSARY AND ABBREVIATIONS  
VO2max  Maximum oxygen consumption 
